DE MARCHIS VERONICA

Their core work

De Marchis Veronica is an Italian private entity — most likely an individual expert or micro-consultancy operating under a personal company structure — that has participated in two thematically distinct MSCA-funded research consortia. In CHARMED, the contribution was oriented around green micro-environments and their measurable effects on aging, well-being, and health tourism. In ACORN, the focus shifted sharply toward biomedical chemistry, specifically antibody-drug conjugates and bioconjugation techniques for nanoparticle-based therapeutics. The organization appears to bring cross-disciplinary bridging or coordination capacity to these consortia rather than deep single-domain laboratory expertise.

What they specialise in

How they've shifted over time

This entity's two projects sit at opposite ends of life sciences: the first (CHARMED, 2017) was rooted in environmental health, aging, and wellness tourism — a soft, applied field. By 2018, the second project (ACORN) had moved into hard pharmaceutical chemistry — nanoparticles, CO-releasing molecules, and antibody-drug conjugates. The shift is sharp enough to suggest the organization is not a specialist research lab but rather a flexible expert contributor whose value to consortia is not domain-specific. No mid-period data exists to confirm whether this trajectory continues.

The jump from wellness environments to pharmaceutical bioconjugation within a single year suggests this entity follows research funding opportunities across health sub-sectors rather than building a cumulative specialist profile — future collaborations could span any area of applied biomedical research.

How they like to work

This organization has never held a coordinator role and participates exclusively as a consortium member, consistent with a specialist contributor or expert-for-hire model. With 23 unique partners across only 2 projects, the network is broad relative to volume, suggesting engagement with large, multi-partner MSCA consortia. There is no evidence of repeated partnerships, pointing to an open, opportunistic collaboration strategy rather than a stable research network.

The organization has worked with 23 distinct consortium partners across 8 countries, an unusually wide network for just two projects, reflecting the large staff-exchange consortia typical of MSCA-RISE schemes. No single geographic focus is discernible from the available data.

What sets them apart

This entity's distinguishing trait is its willingness — and apparent capacity — to contribute across fields as different as environmental health tourism and nanoparticle drug chemistry within a one-year span, which is unusual even for generalist consultancies. For consortium builders, this may signal a contributor who covers project management, dissemination, or cross-sector translation rather than bench research. Given the private company structure and individual-sounding name, it likely offers the flexibility of a sole expert without the overhead of an institution.

Highlights from their portfolio

• ACORN
  Higher-funded of the two projects (EUR 65,000) and represents a significant thematic leap into pharmaceutical nanoparticle chemistry and antibody-drug conjugates — the most technically specialized work in this organization's portfolio.
• CHARMED
  Covers an unusual intersection of environmental science, aging research, and health tourism — a niche applied domain with growing relevance to regional health policy and wellness industries.